Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Share-based Compensation (2020 - 2025)

Historic Share-based Compensation for Janux Therapeutics (JANX) over the last 6 years, with Q3 2025 value amounting to $9.0 million.

  • Janux Therapeutics' Share-based Compensation fell 4122.31% to $9.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $37.0 million, marking a year-over-year increase of 1825.48%. This contributed to the annual value of $33.0 million for FY2024, which is 6505.87% up from last year.
  • Per Janux Therapeutics' latest filing, its Share-based Compensation stood at $9.0 million for Q3 2025, which was down 4122.31% from $11.0 million recorded in Q2 2025.
  • In the past 5 years, Janux Therapeutics' Share-based Compensation ranged from a high of $15.4 million in Q3 2024 and a low of $123000.0 during Q1 2021
  • In the last 5 years, Janux Therapeutics' Share-based Compensation had a median value of $4.6 million in 2022 and averaged $5.7 million.
  • As far as peak fluctuations go, Janux Therapeutics' Share-based Compensation surged by 6375000.0% in 2021, and later crashed by 4122.31% in 2025.
  • Quarter analysis of 5 years shows Janux Therapeutics' Share-based Compensation stood at $2.9 million in 2021, then surged by 42.83% to $4.2 million in 2022, then grew by 6.61% to $4.5 million in 2023, then skyrocketed by 39.44% to $6.3 million in 2024, then soared by 44.68% to $9.0 million in 2025.
  • Its last three reported values are $9.0 million in Q3 2025, $11.0 million for Q2 2025, and $10.7 million during Q1 2025.